A Study of Hemay005 in Adult With Atopic Dermatitis
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
A multicenter, randomized, double-blind, placebo-controlled, phase II study to evaluate the
efficacy and safety of Hemay005 tablet in the treatment of moderate to severe atopic
dermatitis.